Suppr超能文献

药物与热疗的治疗潜力。

Potential for therapy of drugs and hyperthermia.

作者信息

Hahn G M

出版信息

Cancer Res. 1979 Jun;39(6 Pt 2):2264-8.

PMID:87263
Abstract

The interaction of hyperthermia (41--45 degrees C) and chemotherapeutic agents frequently results in increased cytotoxicity over that predicted for an additive effect, although to date only a very limited number of drugs have been examined for such a possible interaction. At 42 degrees C, the upper limit of temperature useful for whole-body hyperthermia, the most promising agents of those examined to date appear to be the nitrosoureas and cis-platinum. Insufficient data exist for cyclophosphamide, whose long plasma half-life makes it an attractive candidate. Localized heating seems optimum at higher temperatures (43--45 degrees C). At these temperatures, not only those drugs effective at 42 degrees C but particularly bleomycin and possibly amphotericin B become candidates. No data exist in the literature on possible "thermic sensitizers," i.e., drugs which are noncytotoxic at 37 degrees C but which become effective at elevated temperatures. Two special cases are Adriamycin and actinomycin D. These drugs may be contraindicated for clinical use, since not only synergism but also protection by hyperthermia have been demonstrated, depending upon the time-sequence relationships of the heat and drug treatments.

摘要

高温(41 - 45摄氏度)与化疗药物的相互作用常常导致细胞毒性增强,超过单纯相加效应所预测的程度,不过迄今为止,仅对极少数药物进行过这种可能相互作用的研究。在42摄氏度(全身热疗的有效温度上限)时,迄今为止所研究的最具潜力的药物似乎是亚硝基脲类和顺铂。关于环磷酰胺的数据不足,其较长的血浆半衰期使其成为一个有吸引力的候选药物。局部加热在较高温度(43 - 45摄氏度)时似乎最为适宜。在这些温度下,不仅是那些在42摄氏度时有效的药物,特别是博来霉素以及可能还有两性霉素B都成为了候选药物。文献中尚无关于可能的“热增敏剂”的数据,即那些在37摄氏度时无细胞毒性但在升高温度时变得有效的药物。有两个特殊例子是阿霉素和放线菌素D。这些药物可能在临床使用上存在禁忌,因为不仅已经证明了协同作用,而且热疗的保护作用也取决于热疗和药物治疗的时间顺序关系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验